Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
8
SUSRF Quote, Financials, Valuation and Earnings
Last price:
$3.63
Seasonality move
:
25.85%
Day range:
$3.50 - $3.50
52-week range:
$3.16 - $16.33
Dividend yield:
0%
P/E ratio:
27.26x
P/S ratio:
1.85x
P/B ratio:
0.39x
Volume:
--
Avg. volume:
3.1K
1-year change:
-72.59%
Market cap:
$178.3M
Revenue:
$83.6M
EPS (TTM):
$0.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
-- | -- | -- | -- | -- |
|
BOVNF
BioInvent International AB
|
-- | -- | -- | -- | -- |
|
BRCTF
BioArctic AB
|
-- | -- | -- | -- | -- |
|
CAMRF
Camurus AB
|
-- | -- | -- | -- | -- |
|
HNSBF
Hansa Biopharma AB
|
-- | -- | -- | -- | -- |
|
ORXOY
Orexo AB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
$3.50 | -- | $178.3M | 27.26x | $0.00 | 0% | 1.85x |
|
BOVNF
BioInvent International AB
|
$3.29 | -- | $216.4M | -- | $0.00 | 0% | 8.69x |
|
BRCTF
BioArctic AB
|
$34.00 | -- | $3B | 32.11x | $0.00 | 0% | 16.28x |
|
CAMRF
Camurus AB
|
$64.23 | -- | $3.8B | 49.63x | $0.00 | 0% | 16.54x |
|
HNSBF
Hansa Biopharma AB
|
$2.91 | -- | $290.2M | -- | $0.00 | 0% | 12.08x |
|
ORXOY
Orexo AB
|
$3.00 | -- | $104.1M | -- | $0.00 | 0% | 1.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
0.04% | 1.343 | 0.03% | 2.78x |
|
BOVNF
BioInvent International AB
|
1.54% | -0.944 | 0.53% | 6.82x |
|
BRCTF
BioArctic AB
|
2.31% | 0.968 | 0.18% | 3.14x |
|
CAMRF
Camurus AB
|
2.52% | 0.192 | 0.28% | 9.80x |
|
HNSBF
Hansa Biopharma AB
|
254.41% | 1.407 | 39.58% | 1.00x |
|
ORXOY
Orexo AB
|
171.74% | -0.131 | 97.86% | 1.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
$15.8M | $4M | 1.46% | 1.47% | 14.59% | -$1.6M |
|
BOVNF
BioInvent International AB
|
-- | -$14.1M | -37.24% | -37.89% | -4030.98% | -$11.2M |
|
BRCTF
BioArctic AB
|
$12.7M | -$2.6M | 57.61% | 59.48% | -18.55% | -$2.5M |
|
CAMRF
Camurus AB
|
$54.8M | $24.9M | 21.21% | 21.63% | 41.84% | $14.2M |
|
HNSBF
Hansa Biopharma AB
|
$1.1M | -$15.5M | -135.05% | -- | -480.21% | -$9.8M |
|
ORXOY
Orexo AB
|
$11.4M | -$2.2M | -54.08% | -134.37% | -18.19% | $240.6K |
Surgical Science Sweden AB vs. Competitors
-
Which has Higher Returns SUSRF or BOVNF?
BioInvent International AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -3891.55%. Surgical Science Sweden AB's return on equity of 1.47% beat BioInvent International AB's return on equity of -37.89%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M BOVNFBioInvent International AB-- -$0.21 $73.8M -
What do Analysts Say About SUSRF or BOVNF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioInvent International AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than BioInvent International AB, analysts believe Surgical Science Sweden AB is more attractive than BioInvent International AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 BOVNFBioInvent International AB0 0 0 -
Is SUSRF or BOVNF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioInvent International AB has a beta of 6.936, suggesting its more volatile than the S&P 500 by 593.641%.
-
Which is a Better Dividend Stock SUSRF or BOVNF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioInvent International AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. BioInvent International AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or BOVNF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than BioInvent International AB quarterly revenues of $348.9K. Surgical Science Sweden AB's net income of $2.1M is higher than BioInvent International AB's net income of -$13.6M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 27.26x while BioInvent International AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.85x versus 8.69x for BioInvent International AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.85x 27.26x $27.7M $2.1M BOVNFBioInvent International AB8.69x -- $348.9K -$13.6M
-
Which has Higher Returns SUSRF or BRCTF?
BioArctic AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -65.15%. Surgical Science Sweden AB's return on equity of 1.47% beat BioArctic AB's return on equity of 59.48%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M BRCTFBioArctic AB90.84% -$0.10 $214.3M -
What do Analysts Say About SUSRF or BRCTF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than BioArctic AB, analysts believe Surgical Science Sweden AB is more attractive than BioArctic AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 BRCTFBioArctic AB0 0 0 -
Is SUSRF or BRCTF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SUSRF or BRCTF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or BRCTF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than BioArctic AB quarterly revenues of $14M. Surgical Science Sweden AB's net income of $2.1M is higher than BioArctic AB's net income of -$9.1M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 27.26x while BioArctic AB's PE ratio is 32.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.85x versus 16.28x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.85x 27.26x $27.7M $2.1M BRCTFBioArctic AB16.28x 32.11x $14M -$9.1M
-
Which has Higher Returns SUSRF or CAMRF?
Camurus AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of 33.97%. Surgical Science Sweden AB's return on equity of 1.47% beat Camurus AB's return on equity of 21.63%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M CAMRFCamurus AB91.93% $0.34 $449M -
What do Analysts Say About SUSRF or CAMRF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Camurus AB, analysts believe Surgical Science Sweden AB is more attractive than Camurus AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 CAMRFCamurus AB0 0 0 -
Is SUSRF or CAMRF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.658%.
-
Which is a Better Dividend Stock SUSRF or CAMRF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or CAMRF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are smaller than Camurus AB quarterly revenues of $59.6M. Surgical Science Sweden AB's net income of $2.1M is lower than Camurus AB's net income of $20.2M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 27.26x while Camurus AB's PE ratio is 49.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.85x versus 16.54x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.85x 27.26x $27.7M $2.1M CAMRFCamurus AB16.54x 49.63x $59.6M $20.2M
-
Which has Higher Returns SUSRF or HNSBF?
Hansa Biopharma AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -481.29%. Surgical Science Sweden AB's return on equity of 1.47% beat Hansa Biopharma AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M HNSBFHansa Biopharma AB34.72% -$0.18 $38.6M -
What do Analysts Say About SUSRF or HNSBF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Hansa Biopharma AB, analysts believe Surgical Science Sweden AB is more attractive than Hansa Biopharma AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 HNSBFHansa Biopharma AB0 0 0 -
Is SUSRF or HNSBF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.764%.
-
Which is a Better Dividend Stock SUSRF or HNSBF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or HNSBF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than Hansa Biopharma AB quarterly revenues of $3.2M. Surgical Science Sweden AB's net income of $2.1M is higher than Hansa Biopharma AB's net income of -$15.6M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 27.26x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.85x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.85x 27.26x $27.7M $2.1M HNSBFHansa Biopharma AB12.08x -- $3.2M -$15.6M
-
Which has Higher Returns SUSRF or ORXOY?
Orexo AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -33.67%. Surgical Science Sweden AB's return on equity of 1.47% beat Orexo AB's return on equity of -134.37%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M ORXOYOrexo AB92.89% -$0.12 $29M -
What do Analysts Say About SUSRF or ORXOY?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Orexo AB, analysts believe Surgical Science Sweden AB is more attractive than Orexo AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 ORXOYOrexo AB0 0 0 -
Is SUSRF or ORXOY More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.934%.
-
Which is a Better Dividend Stock SUSRF or ORXOY?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or ORXOY?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than Orexo AB quarterly revenues of $12.2M. Surgical Science Sweden AB's net income of $2.1M is higher than Orexo AB's net income of -$4.1M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 27.26x while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.85x versus 1.31x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.85x 27.26x $27.7M $2.1M ORXOYOrexo AB1.31x -- $12.2M -$4.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
Sell
6
ODC alert for Dec 10
Oil-Dri Corp. of America [ODC] is up 3.07% over the past day.
Buy
84
PAAS alert for Dec 10
Pan American Silver Corp. [PAAS] is up 0.5% over the past day.
